• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利奈唑胺治疗结核性脑膜炎的疗效：一项荟萃分析。

Efficacy of linezolid in the treatment of tuberculous meningitis: a meta-analysis.

作者信息

Liu Xiaoshu, Tang Daoyan, Qi Min, He Jian-Qing

机构信息

Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.

Department of Respiratory and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

出版信息

Arch Med Sci. 2024 Jun 29;20(3):1038-1042. doi: 10.5114/aoms/189905. eCollection 2024.

DOI:10.5114/aoms/189905
PMID:39050154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11264080/
Abstract

INTRODUCTION

Tuberculous meningitis (TBM) is a severe extra-pulmonary tuberculosis with high fatality. This meta-analysis aimed to assess the impact of linezolid on TBM treatment outcomes.

METHODS

We searched multiple databases for studies published up to May 18, 2024 comparing the effects of linezolid on TBM. Meta-analysis was conducted using Review Manager 5.4.

RESULTS

Our findings indicated that linezolid may reduce treatment failure risk (RR = 0.42 (0.20, 0.89), = 0.02) and improve temperature recovery (RR = 1.56 (1.21, 2.02), < 0.001) in TBM patients.

CONCLUSIONS

The analysis suggests a positive association between linezolid treatment and therapeutic improvements, with no significant adverse reactions reported.

摘要

引言

结核性脑膜炎（TBM）是一种严重的肺外结核病，病死率很高。本荟萃分析旨在评估利奈唑胺对TBM治疗结果的影响。

方法

我们检索了多个数据库，以查找截至2024年5月18日发表的比较利奈唑胺对TBM影响的研究。使用Review Manager 5.4进行荟萃分析。

结果

我们的研究结果表明，利奈唑胺可能会降低TBM患者的治疗失败风险（RR = 0.42（0.20，0.89），P = 0.02）并改善体温恢复情况（RR = 1.56（1.21，2.02），P < 0.001）。

结论

分析表明利奈唑胺治疗与治疗改善之间存在正相关，且未报告有明显不良反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb2b/11264080/689cd9cca2ab/AMS-20-3-189905-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb2b/11264080/689cd9cca2ab/AMS-20-3-189905-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb2b/11264080/689cd9cca2ab/AMS-20-3-189905-g001.jpg

相似文献

1
Efficacy of linezolid in the treatment of tuberculous meningitis: a meta-analysis.利奈唑胺治疗结核性脑膜炎的疗效：一项荟萃分析。
Arch Med Sci. 2024 Jun 29;20(3):1038-1042. doi: 10.5114/aoms/189905. eCollection 2024.
2
Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China.中国深圳的利奈唑胺治疗方案使利福平/耐多药结核性脑膜炎的死亡率降低。
BMC Infect Dis. 2021 Sep 28;21(1):1015. doi: 10.1186/s12879-021-06705-4.
3
Case report: Successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid.病例报告：康替唑胺成功治疗1例对利奈唑胺不耐受的结核性脑膜炎患者。
Front Med (Lausanne). 2023 Oct 19;10:1224179. doi: 10.3389/fmed.2023.1224179. eCollection 2023.
4
A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.一项评估增加剂量利福平联合或不联合阿司匹林与左氧氟沙星治疗人类免疫缺陷病毒相关性结核性脑膜炎的安全性和耐受性的 2A 期临床试验：LASER-TBM 试验。
Clin Infect Dis. 2023 Apr 17;76(8):1412-1422. doi: 10.1093/cid/ciac932.
5
Safety and efficacy of high-dose rifampicin in the management of tuberculosis meningitis: Systematic review and meta-analysis.高剂量利福平治疗结核性脑膜炎的安全性和有效性：系统评价和荟萃分析。
Int J Mycobacteriol. 2021 Jul-Sep;10(3):312-319. doi: 10.4103/ijmy.ijmy_135_21.
6
Linezolid is Associated with Improved Early Outcomes of Childhood Tuberculous Meningitis.利奈唑胺与儿童结核性脑膜炎早期预后改善相关。
Pediatr Infect Dis J. 2016 Jun;35(6):607-10. doi: 10.1097/INF.0000000000001114.
7
Central Inflammatory Cytokines in Tuberculous Meningitis: A Systematic Review and Meta-analysis.结核性脑膜炎中的中枢炎症细胞因子：系统评价与荟萃分析
J Interferon Cytokine Res. 2022 Mar;42(3):95-107. doi: 10.1089/jir.2021.0176.
8
A 43-year systematic review and meta-analysis: case-fatality and risk of death among adults with tuberculous meningitis in Africa.一项为期43年的系统评价与荟萃分析：非洲成人结核性脑膜炎患者的病死率和死亡风险
J Neurol. 2014 May;261(5):851-65. doi: 10.1007/s00415-013-7060-6. Epub 2013 Aug 21.
9
Efficacy and safety of intrathecal dexamethasone combined with isoniazid in the treatment of tuberculous meningitis: a meta-analysis.鞘内注射地塞米松联合异烟肼治疗结核性脑膜炎的疗效及安全性：一项荟萃分析。
BMC Neurol. 2024 Jun 10;24(1):194. doi: 10.1186/s12883-024-03701-4.
10
Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis.利奈唑胺对患有危及生命的结核性脑膜炎的患者显示出迅速且显著的治疗效果。
Antimicrob Agents Chemother. 2014 Oct;58(10):6297-301. doi: 10.1128/AAC.02784-14. Epub 2014 Aug 4.

引用本文的文献

1
Clinical efficacy of linezolid in the treatment of tuberculous meningitis: a retrospective analysis and literature review.利奈唑胺治疗结核性脑膜炎的临床疗效：一项回顾性分析及文献综述
BMC Infect Dis. 2025 Apr 5;25(1):467. doi: 10.1186/s12879-025-10874-x.
2
Epidemiology, Pathogenesis, Clinical Manifestations, and Management Strategies of Tuberculous Meningitis.结核性脑膜炎的流行病学、发病机制、临床表现及治疗策略
Arch Intern Med Res. 2025;8(1):48-58. doi: 10.26502/aimr.0195. Epub 2025 Feb 10.

本文引用的文献

1
Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis.脑脊液中利奈唑胺定量液相色谱串联质谱测定法的验证及其在HIV相关结核性脑膜炎患者中的应用。
Heliyon. 2023 Nov 7;9(11):e21962. doi: 10.1016/j.heliyon.2023.e21962. eCollection 2023 Nov.
2
Escalate: Linezolid as an add on treatment in the intensive phase of tubercular meningitis. A randomized controlled pilot trial.升级治疗：利奈唑胺联合治疗结核性脑膜炎强化期。一项随机对照的初步试验。
Tuberculosis (Edinb). 2023 Sep;142:102351. doi: 10.1016/j.tube.2023.102351. Epub 2023 Jun 30.
3
Activity of vancomycin combined with linezolid against clinical vancomycin-resistant strains.
万古霉素联合利奈唑胺对临床耐万古霉素菌株的活性。
Arch Med Sci. 2020 Jul 3;19(1):189-193. doi: 10.5114/aoms.2020.96400. eCollection 2023.
4
A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.一项评估增加剂量利福平联合或不联合阿司匹林与左氧氟沙星治疗人类免疫缺陷病毒相关性结核性脑膜炎的安全性和耐受性的 2A 期临床试验：LASER-TBM 试验。
Clin Infect Dis. 2023 Apr 17;76(8):1412-1422. doi: 10.1093/cid/ciac932.
5
Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis.利奈唑胺暴露与耐多药结核病患者的血液学毒性相关。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0040822. doi: 10.1128/aac.00408-22. Epub 2022 Aug 2.
6
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).一种用于耐多药结核病的6个月全口服治疗方案：一项多中心随机对照临床试验（NExT研究）
Am J Respir Crit Care Med. 2022 May 15;205(10):1214-1227. doi: 10.1164/rccm.202107-1779OC.
7
Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China.中国深圳的利奈唑胺治疗方案使利福平/耐多药结核性脑膜炎的死亡率降低。
BMC Infect Dis. 2021 Sep 28;21(1):1015. doi: 10.1186/s12879-021-06705-4.
8
The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes.结核性脑膜炎的当前全球形势：流行病学、诊断、治疗及预后
Wellcome Open Res. 2019 Nov 5;4:167. doi: 10.12688/wellcomeopenres.15535.1. eCollection 2019.
9
Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis.利奈唑胺在结核分枝杆菌感染的小鼠模型中的药效学相关性及其毒性。
J Infect Dis. 2021 Jun 4;223(11):1855-1864. doi: 10.1093/infdis/jiaa016.
10
Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.利福平在人类结核病中的临床药代动力学和药效学。
Clin Pharmacokinet. 2019 Sep;58(9):1103-1129. doi: 10.1007/s40262-019-00764-2.